Evidence map›Paper›PMID 40793837›Full record

ArticleEmerging microbes & infections2025

Emerging

Predrag Stojanovic, Margriet Kraakman, Daan W Notermans, James Groot, Céline Harmanus, Joffrey van Prehn, Mark Wilcox, Ed J Kuijper, Wiep Klaas Smits, Dutch National Expertise Centre for Clostridioides difficile infections group

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Emerging microbes & infections, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Frontiers in microbiology · 2026
    Article
  3. Dominance of toxigenicFrontiers in microbiology · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Predrag StojanovicCenter of Microbiology, Institute for Public Health Niš, Niš, Serbia (National Reference Laboratory for Anaerobic Infections-Clostridioides difficile).
Margriet KraakmanLeiden University Center for Infectious Diseases, Leiden University Medical Center (LUMC), Leiden, The Netherlands.
Daan W NotermansCentre for Infectious Disease Control (CIb), National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands.
James GrootCentre for Infectious Disease Control (CIb), National Institute for Public Health and the Environment (RIVM), Bilthoven, The Netherlands.
Céline HarmanusLeiden University Center for Infectious Diseases, Leiden University Medical Center (LUMC), Leiden, The Netherlands.
Joffrey van PrehnLeiden University Center for Infectious Diseases, Leiden University Medical Center (LUMC), Leiden, The Netherlands.
Mark WilcoxLeeds Teaching Hospitals and University of Leeds, Leeds, UK.
Ed J KuijperLeiden University Center for Infectious Diseases, Leiden University Medical Center (LUMC), Leiden, The Netherlands.
Wiep Klaas SmitsLeiden University Center for Infectious Diseases, Leiden University Medical Center (LUMC), Leiden, The Netherlands.
Dutch National Expertise Centre for Clostridioides difficile infections groupCenter of Microbiology, Institute for Public Health Niš, Niš, Serbia (National Reference Laboratory for Anaerobic Infections-Clostridioides difficile).

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

End 2023, the UK Health Security Agency sent an alert about a new hypervirulent

Indexed as

Clostridioides difficileClostridium InfectionsDrug Resistance, BacterialMetronidazoleAdultAgedAged, 80 and overAnti-Bacterial AgentsDisease OutbreaksFemaleHumansMaleMicrobial Sensitivity TestsMiddle AgedMultilocus Sequence TypingRibotypingAnti-Bacterial AgentsMetronidazoleClostridioides difficilemetronidazole resistanceribotype 955SerbiaSurveillance

Identifiers

PMID40793837
PMCPMC12409861

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.